Safety & Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution

Phase 1

Completed

• Conditions: Pellucid Marginal Corneal Degeneration; Corneal Degeneration; Keratoconus; Corneal Ectasia
• Interventions: Combination Product: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution

• Registration Number: NCT04667572
• Lead Sponsor: Cornea Associates of Texas

Brief Summary

Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Collagen Cross-linking in Eyes With Corneal Thinning Conditions

Detailed Description

Patients with progressive keratoconus, pellucid marginal degeneration, or at risk for post-refractive corneal ectasia will be recruited and undergo epithelial-on corneal crosslinking with the Peschke PXL-330 system using pulsed, accelerated energy delivery. Patients will undergo monitoring for 1 year, with serial measurements of corneal topography, visual acuity, pachymetry, and visual function.

Study Timeline

• Study First Submitted: 2020-12-02
• Study First Submitted QC: 2020-12-08
• Study First Posted: 2020-12-14
• Study Start: 2021-02-01
• Primary Completion: 2024-08-21
• Study Completion: 2024-08-21
• Status Verified: 2025-02
• Last Update Submitted: 2025-02-10
• Last Update Posted: 2025-02-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 249

Inclusion Criteria

• 8 years of age or older
• Signed written informed consent
• Willingness and ability to comply with schedule for follow-up visits
• Contact Lens Wearers Only:
• Removal of contact lenses (if applicable) for the required period of time prior to the screening refraction: Soft, discontinue 3 days; Soft Extended Wear, discontinue 3 days; Soft Toric, discontinue 3 days; Rigid gas permeable, discontinue 2 Weeks (subjects who cannot function without wearing their contact lenses, may forgo discontinuation of contact lenses)

And one or more of the following:

• Presence of central or inferior steepening.
• Axial topography consistent with keratoconus, post-surgical ectasia, or pellucid marginal degeneration
• Presence of one or more findings associated with keratoconus or pellucid marginal degeneration, such as: Fleischer ring, Vogt's striae, Decentered corneal apex, Munson's sign, Rizzutti's sign, Apical Corneal scarring consistent with Bowman's breaks, Scissoring of the retinoscopic reflex, Crab-claw appearance on topography
• Steepest keratometry (Kmax) value ≥ 47.20 D
• I-S keratometry difference > 1.5 D on the Pentacam/Orbscan map or topography map
• Posterior corneal elevation >16 microns
• Thinnest corneal point >300 microns

Exclusion Criteria

• Eyes classified as either normal or atypical normal on the severity grading scheme.
• Corneal thickness < 300 microns measured by ultrasonic pachymetry or pentacam.
• Previous ocular condition (other than refractive error) in the eye(s) to be treated that may predispose the eye for future complications, for example: History of or active corneal disease (e.g., herpes simplex, herpes zoster keratitis, recurrent erosion syndrome, etc.) Clinically significant corneal scarring in the CXL treatment zone that is not related to keratoconus or, in the investigator's opinion, will interfere with the cross-linking procedure.
• Pregnancy (including plan to become pregnant) or lactation during the course of the study
• A known sensitivity to study medications
• Patients with nystagmus or any other condition that would prevent a steady gaze during the CXL treatment or other diagnostic tests.
• Patients with a current condition that, in the physician's opinion, would interfere with or prolong epithelial healing

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Pulsed 5mW/cm2	PXL-330 Platinum device for crosslinking with Peschke riboflavin solution	5mW/cm2, with pulsed mode, 10 seconds on, 10 second off, for 36 minute total treatment time
Pulsed 8mW/cm2	PXL-330 Platinum device for crosslinking with Peschke riboflavin solution	8mW/cm2, with pulsed mode, 10 seconds on, 10 second off, for 22 minute and 30 seconds total treatment time

Primary Outcome Measures

Name	Time	Method
K-Max	12 Months	Change in K-Max measured by corneal topography, compared to baseline
K-Mean	12 Months	Change in K-Mean measured by corneal topography, compared to baseline

Secondary Outcome Measures

Name	Time	Method
Uncorrected Visual Acuity	12 Months	Change in uncorrected corrected visual acuity using snellen measurements, compared to baseline
Best Corrected Visual Acuity	12 Months	Change in best corrected visual acuity using snellen measurements, compared to baseline
Central Pachymetry	12 Months	Change in central pachymetry, measured by Pentacam compared to baseline

Trial Locations

Locations (1)

Cornea Associates of Texas; 🇺🇸 Dallas, Texas, United States